-+ 0.00%
-+ 0.00%
-+ 0.00%

Ganli Pharmaceutical announced that Ganli Pharmaceutical Shandong Co., Ltd., a wholly-owned subsidiary of the company, recently received the GZC8072 tablet “Drug Clinical Trial Approval Notice” for new indications issued by the State Drug Administration and agreed to carry out clinical trials for type 2 diabetes. In the next phase, clinical trials of this product will be carried out in accordance with the relevant regulations of national drug registration.

Zhitongcaijing·09/03/2026 08:33:17
Listen to the news
Ganli Pharmaceutical announced that Ganli Pharmaceutical Shandong Co., Ltd., a wholly-owned subsidiary of the company, recently received the GZC8072 tablet “Drug Clinical Trial Approval Notice” for new indications issued by the State Drug Administration and agreed to carry out clinical trials for type 2 diabetes. In the next phase, clinical trials of this product will be carried out in accordance with the relevant regulations of national drug registration.